Medical Center Düsseldorf
Industry / private company
Location:
Düsseldorf,
Germany (DE)
ISNI: -
Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785)) (2022)
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al.
Journal article, Erratum
EAPC Core Curriculum for Preventive Cardiology (2022)
Wilhelm M, Abreu A, Adami PE, Ambrosetti M, Antonopoulou M, Biffi A, Cavarretta E, et al.
Journal article
Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors (2020)
Lechner K, Von Schacky C, Mckenzie AL, Worm N, Nixdorff U, Lechner B, Kraenkel N, et al.
Journal article
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019)
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al.
Journal article